Barbara A. Lockart

TL;DR: In this paper, the authors describe fertility preservation (FP) utilization by transgender adolescents within a pediatric gender clinic between July 2013 and July 2016, using a retrospective chart review to abstract demographic and clinical information among adolescents initiating gender-affirming hormones, including patient age at initial FP consultation, birth-assigned sex, race/ethnicity, and outcome of FP consultation.

TL;DR: This review summarizes the current task force recommendations for the assessment and management of female reproductive complications after treatment for childhood, adolescent, and young adult cancers and discusses experimental pretreatment as well as post-treatment fertility preservation strategies.

TL;DR: Current task force recommendations for the assessment and management of male reproductive complications after treatment for childhood, adolescent, and young adult cancers are summarized.

TL;DR: The PanCareLIFE Consortium, and in collaboration with the International Late Effects of Childhood Cancer Guideline Harmonization Group, developed a clinical practice guideline for fertility preservation in female patients who were diagnosed with childhood, adolescent, and young adult cancer at age 25 years or younger.

TL;DR: Fertility preservation options for prepubertal patients with fertility altering conditions such as cancer and differences/disorders of sex development are currently limited, but multiple lines of active research hold promise for the future.